Invesco Ltd. Boosts Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Invesco Ltd. increased its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 2,764.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 284,662 shares of the company's stock after buying an additional 274,724 shares during the period. Invesco Ltd. owned about 0.54% of Janux Therapeutics worth $15,241,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Russell Investments Group Ltd. grew its holdings in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after acquiring an additional 599 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Janux Therapeutics by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock valued at $596,000 after acquiring an additional 1,095 shares during the last quarter. Virtu Financial LLC grew its holdings in shares of Janux Therapeutics by 17.5% in the fourth quarter. Virtu Financial LLC now owns 8,769 shares of the company's stock valued at $469,000 after purchasing an additional 1,306 shares in the last quarter. Finally, Avanza Fonder AB bought a new stake in Janux Therapeutics in the fourth quarter worth $139,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. acquired 341,742 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were bought at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now directly owns 9,658,988 shares in the company, valued at $295,951,392.32. This represents a 3.67 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the sale, the insider now owns 82,139 shares of the company's stock, valued at approximately $2,640,768.85. This represents a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,002 shares of company stock worth $348,203 over the last three months. 29.40% of the stock is owned by corporate insiders.

Janux Therapeutics Price Performance

Shares of NASDAQ:JANX traded down $1.44 during trading on Friday, reaching $30.63. 97,414 shares of the company were exchanged, compared to its average volume of 849,281. The business's fifty day simple moving average is $30.20 and its 200-day simple moving average is $43.23. Janux Therapeutics, Inc. has a 12-month low of $22.52 and a 12-month high of $71.71. The firm has a market capitalization of $1.81 billion, a PE ratio of -26.37 and a beta of 3.27.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Lifesci Capital upgraded Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Wedbush restated an "outperform" rating and set a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Finally, Scotiabank cut their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Janux Therapeutics currently has an average rating of "Buy" and an average price target of $95.25.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.